BioWorld MedTech

Feb. 6, 2017

Elekta secures FDA clearance for Venezia cervical cancer treatment device

Elekta AB has received FDA clearance for its Venezia applicator for gynecological brachytherapy. The device is positioned to treat advanced-stage cervical cancer and has had a CE mark since last year. Read More

Wearable micropump from Cambridge cluster disrupts device design

Questions about device class persist regarding accessory guidance final

Seroba raises $108M in first close of third fund

Appointments and advancements

Financings

Product briefs

MDD's Stock Report

Other news to note

MDD's Neurology Extra

Today's news in brief

BioWorld

BioWorld briefs for July 10, 2026.

Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy

BioWorld

News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...

FENS 2026: Shedding light on the sheddome

BioWorld

At the recently opened FENS Forum 2026 in Barcelona – the Federation of European Neuroscience Societies’ flagship congress and Europe’s largest neuroscience...

FENS 2026: Next-gen biologics take on brain disease

BioWorld

Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...

Liver with hepatitis viruses, blood cells

Recombinant vaccine inhibits HBV-associated HCC growth

BioWorld Science

Chronic liver disease and hepatocellular carcinoma (HCC) associated with chronic hepatitis B virus (HBV) are serious health problems in highly endemic areas....